FogPharma rebrands as Parabilis Medicines, as CEO Mathai Mammen highlights next drugs

FogPharma is renaming itself as Parabilis Medicines, announcing a new corporate identity Monday that reflects the imprint left by CEO Mathai Mammen since joining in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Zimmer receives FDA clearance for robotic shoulder system

Listen to the article 2 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: Zimmer Biomet received 510(k) clearance

February 22, 2024

Penn Medicine Nabs $6M NIH Grant to Study Cardiac Cell Development

Credit: iStock/SvetaP DNA double helix: iStock/Kagenmi Researchers at the Perelman School of Medicine at the University of Pennsylvania have received a seven-year, $6 million grant

June 8, 2023

P-BCMA-ALLO1 by F. Hoffmann-La Roche for Relapsed Multiple Myeloma: Likelihood of Approval – Pharmaceutical Technology

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

October 26, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.